Considerations for successful cancer immunotherapy in aged hosts

Vincent Hurez, Álvaro Padrón, Robert Svatek, Tyler J Curiel

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Improvements in understanding cancer immunopathogenesis have now led to unprecedented successes in immunotherapy to treat numerous cancers. Although aging is the most important risk factor for cancer, most pre-clinical cancer immunotherapy studies are undertaken in young hosts. This review covers age-related immune changes as they affect cancer immune surveillance, immunopathogenesis and immune therapy responses. Declining T cell function with age can impede efficacy of age-related cancer immunotherapies, but examples of successful approaches to breach this barrier have been reported. It is further recognized now that immune functions with age do not simply decline, but that they change in potentially detrimental ways. For example, detrimental immune cell populations can become predominant during aging (notably pro-inflammatory cells), the prevalence or function of suppressive cells can increase (notably myeloid derived suppressor cells), drugs can have age-specific effects on immune cells, and attributes of the aged microenvironment can impede or subvert immunity. Key advances in these and related areas will be reviewed as they pertain to cancer immunotherapy in the aged, and areas requiring additional study and some speculations on future research directions will be addressed. We prefer the term Age Related Immune Dysfunction (ARID) as most encompassing the totality of age-associated immune changes.

Original languageEnglish (US)
JournalExperimental Gerontology
DOIs
StateAccepted/In press - Jan 1 2017

Fingerprint

Immunotherapy
Aging of materials
Neoplasms
T-cells
Cells
Pharmaceutical Preparations
Immunity
T-Lymphocytes
Population
Direction compound

Keywords

  • Aging
  • Cancer
  • Immunity
  • Immunotherapy

ASJC Scopus subject areas

  • Biochemistry
  • Aging
  • Molecular Biology
  • Genetics
  • Endocrinology
  • Cell Biology

Cite this

Considerations for successful cancer immunotherapy in aged hosts. / Hurez, Vincent; Padrón, Álvaro; Svatek, Robert; Curiel, Tyler J.

In: Experimental Gerontology, 01.01.2017.

Research output: Contribution to journalArticle

@article{0ab3289039834761b4dd7033ca8f463d,
title = "Considerations for successful cancer immunotherapy in aged hosts",
abstract = "Improvements in understanding cancer immunopathogenesis have now led to unprecedented successes in immunotherapy to treat numerous cancers. Although aging is the most important risk factor for cancer, most pre-clinical cancer immunotherapy studies are undertaken in young hosts. This review covers age-related immune changes as they affect cancer immune surveillance, immunopathogenesis and immune therapy responses. Declining T cell function with age can impede efficacy of age-related cancer immunotherapies, but examples of successful approaches to breach this barrier have been reported. It is further recognized now that immune functions with age do not simply decline, but that they change in potentially detrimental ways. For example, detrimental immune cell populations can become predominant during aging (notably pro-inflammatory cells), the prevalence or function of suppressive cells can increase (notably myeloid derived suppressor cells), drugs can have age-specific effects on immune cells, and attributes of the aged microenvironment can impede or subvert immunity. Key advances in these and related areas will be reviewed as they pertain to cancer immunotherapy in the aged, and areas requiring additional study and some speculations on future research directions will be addressed. We prefer the term Age Related Immune Dysfunction (ARID) as most encompassing the totality of age-associated immune changes.",
keywords = "Aging, Cancer, Immunity, Immunotherapy",
author = "Vincent Hurez and {\'A}lvaro Padr{\'o}n and Robert Svatek and Curiel, {Tyler J}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.exger.2017.10.002",
language = "English (US)",
journal = "Experimental Gerontology",
issn = "0531-5565",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Considerations for successful cancer immunotherapy in aged hosts

AU - Hurez, Vincent

AU - Padrón, Álvaro

AU - Svatek, Robert

AU - Curiel, Tyler J

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Improvements in understanding cancer immunopathogenesis have now led to unprecedented successes in immunotherapy to treat numerous cancers. Although aging is the most important risk factor for cancer, most pre-clinical cancer immunotherapy studies are undertaken in young hosts. This review covers age-related immune changes as they affect cancer immune surveillance, immunopathogenesis and immune therapy responses. Declining T cell function with age can impede efficacy of age-related cancer immunotherapies, but examples of successful approaches to breach this barrier have been reported. It is further recognized now that immune functions with age do not simply decline, but that they change in potentially detrimental ways. For example, detrimental immune cell populations can become predominant during aging (notably pro-inflammatory cells), the prevalence or function of suppressive cells can increase (notably myeloid derived suppressor cells), drugs can have age-specific effects on immune cells, and attributes of the aged microenvironment can impede or subvert immunity. Key advances in these and related areas will be reviewed as they pertain to cancer immunotherapy in the aged, and areas requiring additional study and some speculations on future research directions will be addressed. We prefer the term Age Related Immune Dysfunction (ARID) as most encompassing the totality of age-associated immune changes.

AB - Improvements in understanding cancer immunopathogenesis have now led to unprecedented successes in immunotherapy to treat numerous cancers. Although aging is the most important risk factor for cancer, most pre-clinical cancer immunotherapy studies are undertaken in young hosts. This review covers age-related immune changes as they affect cancer immune surveillance, immunopathogenesis and immune therapy responses. Declining T cell function with age can impede efficacy of age-related cancer immunotherapies, but examples of successful approaches to breach this barrier have been reported. It is further recognized now that immune functions with age do not simply decline, but that they change in potentially detrimental ways. For example, detrimental immune cell populations can become predominant during aging (notably pro-inflammatory cells), the prevalence or function of suppressive cells can increase (notably myeloid derived suppressor cells), drugs can have age-specific effects on immune cells, and attributes of the aged microenvironment can impede or subvert immunity. Key advances in these and related areas will be reviewed as they pertain to cancer immunotherapy in the aged, and areas requiring additional study and some speculations on future research directions will be addressed. We prefer the term Age Related Immune Dysfunction (ARID) as most encompassing the totality of age-associated immune changes.

KW - Aging

KW - Cancer

KW - Immunity

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85034577471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034577471&partnerID=8YFLogxK

U2 - 10.1016/j.exger.2017.10.002

DO - 10.1016/j.exger.2017.10.002

M3 - Article

C2 - 28987644

AN - SCOPUS:85034577471

JO - Experimental Gerontology

JF - Experimental Gerontology

SN - 0531-5565

ER -